Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666328 · ClinicalTrials.gov registry record · Phase 3
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
A Phase 3 study of Hypertension and Hemorrhage, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 37
- Enrollment target
- 17
- Study locations
NCT00666328 is a Phase 3 study of Hypertension and Hemorrhage that has completed, run by The Medicines Company. The registered enrollment target is 37 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT00666328, a Phase 3 study of Hypertension and Hemorrhage, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 37 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure \>160 mmHg) in patients with intracerebral hemorrhage (i.e., bleeding in the brain; stroke).
Conditions Studied
Interventions
- DRUG clevidipine
Study Locations (17)
North Carolina
- Duke University Medical Center - Durham
- Guilford Neurologic - Moses H Cone Health System - Greensboro
Ohio
- Cleveland Clinic Hospitals - Cleveland
- The Ohio State University - Columbus
Other
- Universitatsklinikum Erlangen - Erlangen
- Universitatsklinikum Heidelberg - Heidelberg
District of Columbia
- Washington Hospital Center - Washington D.C.
Hawaii
- The Queens Medical Center - Honolulu
Maryland
- The John Hopkins Hospital - Baltimore
Massachusetts
- Maine Medical Center - Portland
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00666328
The ClinicalTrials.gov registry entry for NCT00666328 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which clevidipine is the first listed.
NCT00666328 reports 17 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT00666328 about?
NCT00666328 is a clinical study titled "Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)". The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure \>160 mmHg) in patients with intracerebral hemorrhage (i.e., bleeding in the brain; stroke).
What is the current status of trial NCT00666328?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 37 participants. The study started on 2008-06. Estimated completion is 2010-04.
What conditions does trial NCT00666328 study?
This clinical trial studies the following conditions: Hypertension, Hemorrhage.
What interventions are being tested in trial NCT00666328?
The interventions under investigation include: clevidipine (DRUG).
Who is sponsoring clinical trial NCT00666328?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666328 being conducted?
This trial has 17 study locations across District of Columbia, Hawaii, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.